US Pharm. 2013;38(5):42.

Galveston, TX—University of Texas researchers have identified a protein (Epac1) that can interfere with the brain’s response to leptin and have created a compound that blocks Epac1’s action. The specially developed compound, tested in laboratory mice, could lead to an antiobesity drug. Mice genetically engineered to be unable to produce Epac1 had better glucose tolerance and lower blood leptin levels, body weights, and body-fat percentages than normal mice. Epac1 is activated by cyclic adenosine monophosphate (AMP), a signaling molecule linked to metabolism and leptin production and secretion. The researchers believe that an understanding of how cyclic AMP acts through Epac1 will generate new pharmaceutical possibilities, including a drug to fight obesity and diabetes.

To comment on this article, contact